FindTrial
Sign In

ONO-7475

DRUG3 trials

Sponsors

Ono Pharmaceutical Co. Ltd

Conditions

Advanced or Metastatic Solid TumorsEGFR Mutation-Related TumorsMetastatic Pancreatic CancerRecurrent Non-Small Cell Lung CancerStage IIIB Non-small Cell Lung CancerStage IIIC Non-Small Cell Lung CancerStage IV Non-small Cell Lung Cancer

Phase 1

Phase 1 Study of ONO-7475 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors
CompletedNCT03730337
Ono Pharmaceutical Co. LtdAdvanced or Metastatic Solid Tumors
Start: 2018-10-17End: 2022-11-22Updated: 2023-10-04
Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer
CompletedNCT06525246
Ono Pharmaceutical Co. LtdEGFR Mutation-Related Tumors, Recurrent Non-Small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer +2
Start: 2021-08-06End: 2025-06-23Updated: 2026-03-13
A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic Cancer
Active, not recruitingNCT06532331
Ono Pharmaceutical Co. LtdMetastatic Pancreatic Cancer
Start: 2023-12-06End: 2028-03-31Target: 87Updated: 2025-04-18

Related Papers

Orderly Regulation of Macrophages and Fibroblasts by Axl in Bleomycin‐Induced Pulmonary Fibrosis in Mice
Journal of Cellular and Molecular Medicine2025-01-015 citations
Abstract CT062: A phase 1 study of tamnorzatinib (ONO-7475), an Axl/Mer dual inhibitor, alone and in combination with nivolumab in patients with advanced or metastatic solid tumors
Cancer Research2024-04-053 citations